In a new study published in Lancet Neurology, researchers at Sahlgrenska Academy have been able to show which blood and cerebrospinal fluid biomarkers that best differentiate between patients with Alzheimer’s disease and controls. Parallel to the study, the researchers developed a large database that gathers data on biomarkers in Alzheimer’s and other forms of dementia.

Alzheimer’s disease is the most common form of dementia. It causes enormous suffering in both the patients and relatives, and the disease costs society more than all cardiovascular and cancer healthcare combined.

An important reason why there currently are no available drugs for Alzheimer’s disease, is that the brain damage begins long before the dementia is diagnosed. This means that patients participating in clinical Alzheimer’s studies often have irreversible damage that cannot be stopped.

Read the full article at Sahlgrenska Academy's webiste.